Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2374697 (GSK)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous Injection
01
Overview
GSK2374697 is a genetically engineered fusion protein consisting of a human domain antibody (AlbudAb) fused to exendin-4, designed to bind with high affinity to human serum albumin. This albumin-binding property extends the systemic exposure and half-life of the drug, making it a long-duration glucagon-like peptide-1 (GLP-1) receptor agonist. The molecule was developed as an antihyperglycemic agent and obesity therapy, with pharmacological effects including reduction in postprandial glucose and insulin levels, delayed gastric emptying, and feedback suppression of endogenous GLP-1 and peptide YY secretion. Clinical studies demonstrated prolonged pharmacokinetics (half-life 6–10 days), expected GLP-1 agonist effects on glucose metabolism, and tolerability consistent with other potent GLP-1 agonists. The drug was investigated for potential use in type 2 diabetes mellitus and weight loss[1][2][5][6].
- Other names
- EXENDIN-4 ALBUDABEXENDIN4 ALBUDABEXENDIN 4 ALBUDAB
02
Targets
Beyond the preview
Go deeper on GSK2374697 (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2374697 (GSK).